Држава: Велика Британија
Језик: Енглески
Извор: MHRA (Medicines & Healthcare Products Regulatory Agency)
Bendroflumethiazide
Mawdsley-Brooks & Company Ltd
C03AA01
Bendroflumethiazide
2.5mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02020100
PACKAGE LEAFLET: INFORMATION FOR THE USER BENDROFLUMETHIAZIDE 2.5 MG TABLETS BP BENDROFLUMETHIAZIDE 5 MG TABLETS BP bendroflumethiazide Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If any of the side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Bendroflumethiazide Tablets are and what they are used for 2. What you need to know before you take Bendroflumethiazide Tablets 3. How to take Bendroflumethiazide Tablets 4. Possible side effects 5. How to store Bendroflumethiazide Tablets 6. Contents of the pack and other information 1. WHAT BENDROFLUMETHIAZIDE TABLETS ARE AND WHAT THEY ARE USED FOR Bendroflumethiazide Tablets contain bendroflumethiazide as the active ingredient. They belong to a group of medicines called thiazide diuretics (water tablets). They may be used to: • reduce fluid retention (oedema) particularly in the heart, kidneys, liver or that caused by medication, by increasing the flow of urine • reduce high blood pressure alone or with other medication. • stop the production of breast milk. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE BENDROFLUMETHIAZIDE TABLETS DO NOT TAKE BENDROFLUMETHIAZIDE TABLETS IF YOU: • are allergic to bendroflumethiazide, thiazides or any of the other ingredients of this medicine (listed in section 6) • have severely impaired kidney or liver function • have high level of calcium in your blood (hypercalcaemia) • have low levels of sodium in your blood (hyponatraemia) • have low levels of potassium in your blood which has not responded to treatment (refractory hypokalaemia) • have had Прочитајте комплетан документ
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Bendroflumethiazide 2.5mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Bendroflumethiazide 2.5 mg per tablet. For excipients, see 6.1. 3. PHARMACEUTICAL FORM Tablet. Bendroflumethiazide 2.5 mg tablets are presented as white flat bevelled edge tablets engraved with the company logo on one side and A268 on the other side. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Oedema: Bendroflumethiazide is indicated in the treatment of oedema associated with conditions such as congestive heart failure, nephrotic syndrome, cirrhosis of the liver. Essential hypertension: Bendroflumethiazide may be used as the sole antihypertensive agent or used concurrently with other specific hypotensive agents whose action it potentiates. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION Route of administration: Oral ADULTS: Oedema: 5.0 - 10.0 mg once daily or on alternate days Maintenance: 2.5 - 5.0 mg two or three times a week Essential hypertension: 2.5 mg in the morning, alone or in conjunction with other antihypertensive agents in more severe hypertension. The dosage should be reduced in the elderly with impaired renal function. CHILDREN: Diuretic - Initial: 0.4 mg per kg of body-weight per day. Maintenance: 0.05 to 0.1 mg per kg of body-weight per day. Antihypertensive: 0.05 to 0.4 mg/kg body-weight per day as a single dose or in two divided daily doses, adjusted according to response. 4.3. CONTRAINDICATIONS Bendroflumethiazide is contra-indicated in patients hypersensitive to this drug or any of the excipients and in patients with severe renal insufficiency, Addison’s disease, refractory hypokalaemia, hyponatraemia, hypercalcaemia, serious hepatic disorders, symptomatic hyperuricaemia and acute porphyria. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE When doses higher than those stated in Section 4.2 Posology and method of administration are given to patients being treated for hypertension, more marked changes in plasma potassium, uric acid, glucose and lipids Прочитајте комплетан документ